The impact of germline variants in DNA repair pathways on survival and temozolomide

toxicity in adults with glioma

Geno Guerra, Ph.D.[1,2,*], George Wendt, B.A.[1], Lucie McCoy, M.P.H.[1], Helen M. Hansen, B.A.[1],
Annette M. Molinaro, Ph.D.[1,2], Terri Rice, M.P.H.[1], Victoria Guan[3], Lianne Capistrano[3], Allison
Hsieh[3], Veruna Kalsi[3], Jaimie Sallee[3], Jennie W. Taylor, M.D., M.P.H.[1,4], Jennifer L. Clarke, M.D.,
M.P.H.[1,4], Eduardo Rodriguez Almaraz M.D.[1,2], Linda Kachuri, Ph.D.[5,6], John K. Wiencke, Ph.D.[1,2],
Jeanette E Eckel-Passow, Ph.D.[7], Robert B. Jenkins, M.D., Ph.D.[8], Margaret Wrensch, Ph.D.[1],
Stephen S. Francis, Ph.D.[1,2,9,**]
9

1. Department of Neurological Surgery, University of California San Francisco, San

Francisco, CA, USA

2. Department of Epidemiology and Biostatistics, University of California San Francisco, San

Francisco, CA, USA

3. School of Pharmacy, University of California San Francisco, San Francisco, CA, USA

4. Department of Neurology, University of California San Francisco, San Francisco, CA, USA

5. Department of Epidemiology & Population Health, Stanford University School of

Medicine, Stanford, CA

6. Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA

7. Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA

8. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA

9. Weill Institute for Neurosciences, University of California San Francisco, San Francisco,

CA, USA

* Corresponding author: geno.guerra@ucsf.edu

** Corresponding author: stephen.francis@ucsf.edu

Abstract:

Gliomas are highly fatal malignant brain tumors with prognostically relevant molecular

subtypes. Genomic instability is a hallmark of cancer, including glioma, and DNA repair

mechanisms are crucial to maintaining cell integrity. Temozolomide (TMZ), which utilizes specific

DNA repair pathways in its mechanism of action, is one of the few standard-of-care drugs with a

meaningful impact on *IDH* wildtype glioblastoma survival. However, its utility in non-glioblastomas

is complicated by temozolomide-induced hypermutation. This study aims to identify if germline

polymorphisms in DNA repair genes are associated with overall survival within glioma subtypes

and if the polymorphisms modify survival in subjects treated with temozolomide.

We utilized genotype data of 2078 adults with glioma collected through the UCSF Adult

Glioma Study, Mayo Clinic, and TCGA, to study 1393 SNPs within 22 specific DNA repair genes

on overall survival for all cases and for those with/without temozolomide exposure during first

course of treatment. All models were fit separately for individuals grouped by major molecular

subtypes.

We identified four germline SNPs (within *MLH1*, *MSH4*, *MSH3*, and *MUTYH*) with a

significant (p<0.00019) polygenic effect on survival, where the presence of at least one SNP

decreased overall survival among grade 2 and 3 glioma cases with *IDH* mutated tumors (Hazard

ratio per unit increase in number of present polymorphic sites, HR-PS=1.52, 95% confidence

interval, CI: 1.26-1.83, p=1.3×10^{-5}). In *IDH* mutant gliomas without somatic 1p/19q chromosomal

arm codeletion, we identified a group of SNPs (in *MSH4*, *ERCC2*, and *ERCC1*) which showed a

stepwise significant improvement on overall survival for each present germline polymorphism

(HR-PS=0.67, 95% CI: 0.56-0.80, p=8.9×10^{-6}).

Within *IDH* mutant glioma cases, we also identified two mutations (rs1540354-T in *MLH1*,

rs71636247-G in *MSH3*) which were significantly associated with decreased overall survival only

amongst those with known temozolomide usage (HR-PS=2.23, 95% CI: 1.55-3.20, p=1.56×10^{-5}),

with no survival effect observed in the non-temozolomide group (HR=0.90, 95% CI: 0.63-1.28,

p=0.56). One SNP in *MSH2* was suggestively associated (p<0.005) with altered *IDH* wildtype

glioblastoma response to temozolomide (rs149630102-T, HR=1.74, 95% CI: 1.27-2.39,

p=0.00052). Suggestive associations for other glioma subtypes are also reported.

We found evidence that germline polygenic alterations within DNA repair pathways may

alter prognosis and potentially modulate temozolomide toxicity in adults with glioma. Further

validation and functional work are warranted to assess if these markers can assist clinicians in

individually tailoring therapeutic treatments for adults with glioma tumors.

Keywords:

glioma, DNA repair, base excision repair, mismatch repair, temozolomide, pharmacogenomics

Funding and acknowledgments:

Work at the University of California, San Francisco, was supported by the National

Institutes of Health (grant numbers T32CA112355, R01CA52689, P50CA097257, R01CA126831,

R01CA139020, and R01CA266676), as well as the Ioglio Collective, the National Brain Tumor

Foundation, the Stanley D. Lewis and Virginia S. Lewis Endowed Chair in Brain Tumor Research,

the Robert Magnin Newman Endowed Chair in Neuro-oncology, and by donations from families

and friends of John Berardi, Helen Glaser, Elvera Olsen, Raymond E. Cooper, and William

Martinusen.

The work at Mayo was supported by National Cancer Institute (NCI) grants CA230712,

P50 CA108961, and CA139020; the National Brain Tumor Society; the Ioglio Collective; the Mayo

Clinic; and the Ting Tsung and Wei Fong Chao Foundation.

This publication was supported by the National Center for Research Resources and the

National Center for Advancing Translational Sciences, National Institutes of Health, through

UCSF-CTSI Grant Number UL1 RR024131. Its contents are solely the authors' responsibility and

do not necessarily represent the official views of the NIH. The authors wish to acknowledge study

participants, the clinicians, and the research staff at the participating medical centers, the UCSF

Cancer Registry, and the UCSF Neurosurgery Tissue Bank.

The collection of cancer incidence data used in this study was supported by the California

Department of Public Health pursuant to California Health and Safety Code Section 103885;

Centers for Disease Control and Prevention's (CDC) National Program of Cancer Registries,

under cooperative agreement 5NU58DP006344; the National Cancer Institute's Surveillance,

Epidemiology and End Results Program under contract HHSN261201800032I awarded to the

University of California, San Francisco, contract HHSN261201800015I awarded to the University

of Southern California, and contract HHSN261201800009I awarded to the Public Health Institute,

Cancer Registry of Greater California. The ideas and opinions expressed herein are those of the

author(s) and do not necessarily reflect the opinions of the State of California, Department of

Public Health, the National Cancer Institute, and the Centers for Disease Control and Prevention

or their Contractors and Subcontractors. All analyses, interpretations, and conclusions reached

in this manuscript from the mortality data are those of the author(s) and not the State of California

Department of Public Health.

The Genotype-Tissue Expression (GTEx) Project was supported by the <u>Common Fund</u> of

the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA,

NIMH, and NINDS. The data used for the analyses described in this manuscript were obtained

from the GTEx Portal on 04/26/23.

The results published here are in whole or part based upon data generated by The Cancer

Genome Atlas managed by the NCI and NHGRI. Information about TCGA can be found at

http://cancergenome.nih.gov.

Declaration of interests:

The authors declare no competing interests.

Authorship:

GG, VG, LC, AH, VK, JS, and SSF conceived of the study. GG and SSF wrote the main

drafts of the manuscript. VG, LC, AG, VK, JS, GG, and SSF conducted literature searches. GG,

GW, and SSF conducted statistical and computational analyses. GG, SSF, JWT, JLC, AMM, JLW,

JEP, RBJ, LK, ERA, and MW advised on result interpretations. The primary data collection

involved LM, HMH, AMM, JLW, TR, JEP, RBJ, JKW, and MW. All authors contributed to,

reviewed, and approved the final manuscript.

Introduction/Background:

Gliomas are a histologically and molecularly diverse group of highly fatal cancers

originating from brain glial cells. Overall, gliomas have an incidence rate of ~6 per 100,000

persons[1]. Along with tumor grade, glioma prognoses can be well stratified by the identification of

somatic markers within the primary tumor, the most prominent features being mutations to

isocitrate dehydrogenase 1 and 2 (*IDH*) genes, and codeletion of the 1p and 19q chromosomal

arms (1p/19q)[2]. The most aggressive subtype, *IDH* wildtype glioblastoma (GBM), has a median

overall survival rate of roughly 1.2 years[3]. The last notable increase in survival coincided with

introducing the chemotherapy agent temozolomide[4].

Polymorphisms within DNA repair genes are strong candidates for a functional role in

carcinogenesis. These genes code for redundant and complex repair mechanisms that identify

and repair errors in our genome induced by internal or external forces to ensure proper DNA base

modification. Proper DNA repair plays a fundamental role in preventing genomic instability in

healthy cells, where instability has been shown to drive tumor development and progression in

almost all cancers[5,6]. Tumor cells rely heavily on DNA repair mechanisms to abate further

damage, such as those from oxidative and replicative stress[7].

Some anti-cancer drugs also rely on the overwhelming damage of tumor DNA as a form

of treatment, and DNA repair mechanisms can inhibit effectiveness and mediate treatment

resistance. Temozolomide (TMZ), a chemotherapy treatment for patients with glioma, is an

alkylating agent that induces DNA damage through the methylation of purine bases within tumor

cells, creating genomic instability upon replication. Along with the O^6-methylguanine-DNA-

methyltransferase (*MGMT*) gene, mismatch repair (MMR), and base-excision repair (BER),

pathways play critical roles in TMZ's mechanism of action by identifying and potentially removing

the alkylated bases, leading to either cell repair or cell death[8]. TMZ has become standard-of-care

in treating glioblastomas, with maximum safe surgical resection and adjuvant radiation therapy.

TMZ has also been used to treat lower-grade gliomas (grades 2 and 3), but its utility has been

controversial. Treatment with temozolomide is associated with hypermutation at the time of

progression in patients with primary grade 2/3 *IDH* mutant glioma, with the tumors exhibiting

thousands of new coding mutations, including somatic defects in DNA repair genes, that generate

a distinctive TMZ-induced hypermutation signature[9,10]. Cells that lack MMR function cannot

recognize alkylated bases, leading to unrepaired DNA alterations distributed throughout the

genome[11]. One study observed that amongst 82 cases, roughly 57% of *IDH* mutant LrGGs treated

with TMZ experienced hypermutation at recurrence, associated with shorter survival[11]. Although

there is still a clinical knowledge gap in characterizing which markers can predispose patients to

TMZ-induced hypermutation, recent findings reveal that somatic *MGMT* promoter methylation

levels in newly diagnosed LrGGs are predictive of hypermutation at recurrence and may serve as

a prospective biomarker to inform clinical decision making[12]. However, beyond *MGMT*, mention

the reasons why some patients develop hypermutation following TMZ treatment while others may

not remain unknown. The impact of germline polymorphisms in MMR and BER pathway genes

on TMZ efficacy/toxicity is poorly defined.

Many germline polymorphisms, particularly SNPs, in genes involved in DNA repair

pathways, have been associated with altered genetic predispositions to cancers, such as glioma,

colorectal, lung, breast, and others[13–16]. Since glioma patients are susceptible to TMZ-induced

hypermutation, we hypothesized that polymorphisms in BER/MMR genes may be associated with

altered glioma survival outcomes. To test this hypothesis, we conducted a large association study

of 1393 SNPs across 22 BER/MMR-associated genes and overall survival in 2078 adults with

common glioma subtypes and further analyzed for TMZ-specific survival effects.

Methods:

Ethics:

Collection of patient samples and associated clinicopathological information was

undertaken with written informed consent and relevant ethical review board approval at the

respective study centers in accordance with the tenets of the Declaration of Helsinki. Specifically

informed consent and ethical board approval was obtained from the UCSF Committee on Human

Research (USA) and the Mayo Clinic Office for Human Research Protection (USA). The diagnosis

of glioma (ICDO-3 codes 9380-9480 or equivalent) was established through histology and somatic

molecular markers in all cases in accordance with World Health Organization guidelines.

Study Populations:

We analyzed three glioma datasets assembled based on genotyping platform and study

population for a total sample size of 2078 cases with available genotyping, molecular subtyping

(*IDH* mutation, 1p/19q codeletion status), tumor grade, treatment, and survival information. The

first set, "AGS-Mayo", included 875 cases from the University of California, San Francisco (UCSF)

Adult Glioma Study (AGS) and Mayo Clinic who were genotyped on the Illumina OncoArray, as

previously described[17–20]. The second dataset, "AGS-i370", included 518 cases from the UCSF

Adult Glioma study genotyped on the Illumina HumanHap370duo panel[19]. The third dataset

included 685 glioma cases from The Cancer Genome Atlas (TCGA), with available molecular data

genotyped on the Affymetrix 6.0 array. Subtype information for the TCGA dataset (*IDH* mutation,

1p/19q codeletion status, *TERT* mutation, primary diagnosis, grade) was downloaded from

Ceccarelli et al. 2016[21]. These datasets data quality control, imputation, and sample selection

details have been previously described[22].

For all analyses, samples were separated into major subtypes using prognostically

significant molecular markers (presence/absence of somatic *IDH* mutation and/or 1p/19q

chromosomal arm codeletion) and primary tumor grades[3]. In total, eight groups of glioma cases

were separately analyzed in the present study, most coarsely separated by *IDH* mutation, and

then further stratified by 1p/19q codeletion status and tumor grade (full description available in

Figure 1). Individuals with unknown grade or *IDH* status were excluded from all analyses.

Recorded temozolomide usage (yes/no) during first round of treatment was available for all glioma

cases from the UCSF AGS and Mayo Clinic datasets. Glioma cases included from the TCGA

were generally treatment naïve.

Study Genes:

We conducted a literature review on DNA repair and temozolomide, specifically on BER

and MMR pathways, to identify genes known or suspected to play a role in these mechanisms.

We searched PubMed, Web of Science, Scopus, and Embase until April 2, 2023. Search

keywords included: "base-excision repair," "germline mutation," "hypermutation," "glioma,"

"mismatch base repair," "single nucleotide polymorphism," "temozolomide," "TMZ mechanism of

action," and their synonyms. Candidate genes were included regardless of any reported

relationship with TMZ. This search identified the following 22 candidate genes: *MSH2*, *MSH3*,

MSH4, *MSH5*, *MSH6*, *MLH1*, *MLH3*, *PMS1*, *PMS2*, *XRCC1*, *XRCC3*, *ERCC1*, *ERCC2*, *LIG1*,

LIG3, *LIG4*, *APEX1*, *ADPRT*, *MBD4*, *POLB*, *OGG1*, and *MUTYH*.

SNP selection:

This study analyzed a total of 1393 SNPs with minor allele frequency (MAF) >0.01

(amongst European populations CEU, TSI, FIN, GBR, and IBS from the 1000 Genomes Project[23])

which were available on all three arrays within the regions 1kb upstream or downstream of any of

the 22 candidate DNA repair genes. To properly adjust for multiple testing, the quantity of

putatively independent SNP signals was estimated using a linkage disequilibrium (LD) $r^2 >= 0.10$

(within European populations) filter for SNPs within each chromosome, resulting in 259 effectively

independent SNPs across the 22 genes. This study therefore used a Bonferroni-adjusted p-value

threshold of $0.05/259 = 0.00019$ to determine strict statistical significance for all survival analyses.

A less stringent threshold of $p<0.005$ was used to highlight potentially important associations.

***Statistical Analysis*:**

Overall survival SNP analysis:

We evaluated the relationship between germline genetic variants within DNA repair genes

and overall survival outcomes of adults with subtype-specific gliomas. Single SNP survival

analyses were conducted using SPACox[24] using Cox proportional hazards (PH) models with

adjustments for age at diagnosis, sex, primary tumor grade, history of radiotherapy (binary),

history of chemotherapy (binary), year of primary diagnosis, and the top 10 genetic ancestry

principal components (PCs). No treatment or year of diagnosis information was available for the

TCGA dataset. SNPs were modeled as continuous dosage values. Analyses were conducted

separately for each of the three glioma datasets (AGS-Mayo, AGS-i370, TCGA) and results were

combined in a fixed-effects meta-analysis using the software METAL[25] to account for study-

specific biases. SNP associations with $p<0.00019$ were considered statistically significant after

multiple testing adjustments, and associations with $p<0.005$ were considered suggestively

important. Within each subtype, SNPs where less than 10 cases carried any copy of the minor

allele across the three studies were removed from consideration.

SNP-Temozolomide interaction analysis:

We aimed to identify germline genetic polymorphisms in the nominated MMR/BER

pathway genes described above. These may interact with temozolomide and alter survival

outcomes only in adults with glioma treated with the drug. Cox PH regression models with an

included SNP-TMZ interaction term were fit using gwasurvivr[26] with further adjustments for age

at diagnosis, sex, tumor grade, radiotherapy, diagnosis year, data source (UCSF AGS or Mayo

Clinic), and the top 10 genetic PCs:

$\lambda(t, X) = \lambda_0(t) \exp(\beta_1 \times \text{SNP} + \beta_2 \times \text{TMZ} + \beta_3 \times \text{TMZ} \times \text{SNP} + \text{adjustment covariates})$

Associations were conducted separately for samples typed on the i370 and Oncoarray chips, and

overall effect sizes were estimated in a fixed-effects meta-analysis.

For each suggestively important SNP-TMZ interaction ($p<0.005$ for β_3), we partitioned

individuals into four groups according to temozolomide usage and presence of the minor allele,

and performed unadjusted Kaplan-Meier (KM) survival analysis on these groups to further confirm

if the candidate SNP was explicitly associated with altered survival outcomes only in those who

received temozolomide, with no survival effect between the two non-temozolomide groups. Only

SNPs with at least ten individuals in each group were included for KM analysis. SNPs with a KM

p-value $p<0.05$ in the temozolomide users' group were retained. Amongst this set, SNPs with a

KM p-value $p<0.05$ in the non-temozolomide users' group were discarded, as there was

insufficient evidence to conclude that survival effects of the polymorphism were temozolomide-

specific.

DNA repair polymorphism burden analysis:

DNA repair mutational burden scores (DRBS) were constructed to obtain estimates of the

cumulative effect of polymorphisms on survival in each of the glioma subtypes. For each subtype

with more than one suggestively important SNP association, highly correlated SNPs were filtered

out (linkage disequilibrium, LD, $r^2 >0.5$, within 500kb), preferentially selecting those with the lowest

p-value amongst suggestive variants ($p<0.005$). For each individual in the subtype, a DRBS was

calculated as the integer count of effect polymorphisms amongst the set suggestive SNPs. For a

subtype with k suggestive SNP associations, the score takes integer values in {0,1,...,k}. The

effect alleles were chosen such that the direction of effect was consistent across all SNPs. Cox

proportional hazard models adjusting for age, sex, grade, data source, and the top 10 genetic

PCs were used to determine the statistical significance of both the continuous DRBS and the

binary >0 versus 0 DRBS on survival outcomes. Significant score associations were determined

using the above multiple testing adjusted p-value threshold of p<0.00019.

Results:

Sample Population:

Table 1 provides a descriptive summary of the 2078 included samples with available

genotyping/covariate information. Sample summaries for each analyzed subgroup can be found

in **Supplementary Tables S1-S8**.

DNA repair SNP associations with overall survival:

IDH mutant glioma:

The median survival time for the 813 included individuals with an *IDH* mutant glioma

(grades 2,3, or 4, and regardless of 1p/19q codeletion) was 11.3 years from primary diagnosis.

Of the 1393 SNPs analyzed for association with *IDH* mutant survival, none reached strict

statistical significance (p<0.00019), however polymorphism in *MLH1* had suggestively important

(meta p<0.005) associations with survival. The top tagging SNP of *MLH1*, based on p-value was

an intron variant, rs4647218-G (Hazard ratio, HR=0.81, 95% confidence interval: 0.61-0.95,

p=0.0035). Carriers of two copies of the G allele had a median survival time of 14.3 years,

compared to 11.2 and 10.5 years for one or zero copies of G, respectively.

Grades 2/3 IDH mutant glioma:

We next measured the survival associations of the MMR/BER DNA repair variant SNPs

within 724 grade 2/3 *IDH* mutant gliomas (regardless of 1p/19q codeletion). The median survival

for individuals with this tumor type was 12.2 years from initial surgery-confirming diagnosis. The

analysis of 1393 SNPs resulted in no significant associations after Bonferroni multiple testing

correction (meta p<0.00019), but SNPs in 5 genes had suggestively (meta p<0.005) important

associations (**Table 2, Supplementary File 1**). Like the overall *IDH* mutant group, the strongest

association was rs4647218-G in *MLH1* (HR=0.73, 95% CI: 0.61-0.88, p=0.0014), where carriers

of two copies of the G allele had a median survival of 16.1 years, compared to 13.3 and 11.4 for

carriers of one or zero copies, respectively. A set of SNPs tagged by rs4949677-A in *MSH4* on

chromosome 1 were associated with increased risk of early death (HR=1.33, 95% CI: 1.07-1.65,

p=0.0018). Carriers of the A/A pair had a median survival time of only 9.2 years, compared to

12.8 and 14.4 for A/T and T/T carriers. A single rare SNP in *MSH3* was also associated with poor

survival outcomes (rs146901049-A, HR=3.28, 95% CI: 1.70-6.33, p=0.0029), with carriers of the

A/G pair (n=21) having a dismal median survival time of only 4.7 years, compared to 13.3 for

carriers of the G/G pair (n=703). However, the low number of individuals carrying the allele should

be considered.   Lastly, the G allele of rs3219489, a missense variant in *MUTYH* on chromosome

1, was suggestively associated with increased survival times (HR=0.69, 95% CI: 0.54-0.88,

p=0.0034). Carriers of any copy of the G allele (n=304) had median survival times of 16.9 years,

compared to 11.3 years for those with the C/C genotype (n=420).

To evaluate the effect of the co-occurrence of these polymorphisms, we constructed a

DRBS, where individuals were grouped based on the quantity of effect polymorphisms (k=4

presented above) they harbor (0 to 4 sites with the 'survival-decreasing' polymorphism). We

defined the four effect polymorphisms as: rs4647218-AA, rs4848677-AA, rs146901049-A,

rs3219489-CC. In a multivariate cox model adjusting for age, sex, grade, data source, and the

top 10 genetic PCs, the per-unit increase in the DRBS was significantly associated with decreased

survival outcomes (HR=1.52, 95% CI: 1.26-1.83, p=1.3×10^{-5}). Individuals carrying 3 of the

reported polymorphisms (n=11) had a median survival time of 3.4 years, compared to 9.3 years

for those carrying 2 polymorphisms (n=146), 12.8 years for those carrying only 1 polymorphism

(n=374), and 20.4 years for those carrying none of the four (n=193) (**Figure 2**). In a similarly

parameterized cox model, individuals having a polymorphism at any of the four sites described

above (n=531) had decreased survival times (median 11.3 years) as compared to those carrying

none of the four polymorphisms (HR=1.80, 95% CI: 1.26-2.59, p=0.0014). No substantial

differences between WHO grade or age at diagnosis were observed between DRBS groups.

Grades 2/3 IDH mutant 1p/19q codeleted glioma:

The median survival of the included 279 individuals with lower grade *IDH* mutant 1p/19q

codeleted gliomas was 17.5 years from diagnosis. A single SNP in *MSH2* had suggestive effects

(p<0.005) on survival outcomes. The intron variant rs12615967-G in *MSH2* was associated with

poor prognosis (HR=2.04, 95% CI: 1.22-3.33, p=0.0032), where carriers of any copy of the G

allele (n=69) had a median survival of 11.3 years, compared to 17.9 years for those with the

common A/A genotype (n=210).

Grades 2/3 IDH mutant 1p/19q non-codeleted glioma:

The median survival of the 418 individuals with grade 2/3 *IDH* mutant gliomas without

somatic 1p/19q codeletion was 10.3 years from diagnosis. SNPs in *MSH4*, *ERCC2*, and *ERCC1*

were suggestively associated (p<0.005) with overall survival. A set of SNPs in an LD block tagged

by rs5745366-T in *MSH4* were suggestively associated with improved survival (HR=0.33, 95%

CI: 0.15-0.72, p=0.0010) where carriers of the C/T genotype (n=26) had a median survival of 13.6

years compared to 9.5 years for those with the common C/C genotype (n=392). Two SNPs in

ERCC2, rs3916804-C and rs3916788-C (LD r^2=0.24) were associated with altered survival. The

first, rs3916804-C, an intron variant was suggestively associated with improved survival

(HR=0.44, 95% CI: 0.28-0.70, p=0.0027), where individuals with the C/T or C/C genotype (n=98)

lived a median 13.0 years post-surgery compared to 8.5 years for those with the T/T genotype

(n=320). The second *ERCC2* SNP, rs3916788-C was suggestively associated with improved

survival times (HR=0.62, 95% CI: 0.47-0.83, p=0.0033), where carriers of the C/C genotype

(n=66) had the longest survival, with 13.0 years post diagnosis, carriers of the C/A genotype

(n=208) had a survival of 11.1 years, and carriers of the A/A genotype (n=144) had a median

survival time of only 6.9 years. Lastly, a set of four SNPs in *ERCC1*, tagged by intron SNP

rs144057986-C, were associated with improved survival outcomes (HR=0.58, 95% CI: 0.42-0.82,

p=0.0045). Individuals carrying any copy of the C polymorphism (n=155) had a median survival

of 13.3 years (95% CI: 11.1-NA), compared to only 8.0 years (95% CI: 6.6-10.5) for those with

the T/T genotype (n=263).

To construct a DRBS, individuals were grouped based on the quantity of polymorphisms

(k=4 presented above) they harbor (0 to 4 sites with 'survival-increasing' polymorphism).

Individuals carrying 3 or 4 of the reported polymorphisms (n=40) had a median survival time of

14.5 years, compared to 11.5 years for those carrying 2 polymorphisms (n=147), 9.7 years for

those carrying only 1 polymorphism (n=135), and 6.4 years for those carrying none of the four

(n=96) (**Figure 3**). In a multivariate cox model adjusting for age, sex, grade, data source, and the

top 10 genetic PCs, individuals having a polymorphism at any of the four sites described above

(n=322) had significantly improved survival times as compared to those carrying none of the four

polymorphisms (n=96) (HR=0.47, 95% CI: 0.33-0.69, p=8.07x10^{-5}). In a similarly parameterized

cox model, the per-unit increase in the continuous DRBS was also significantly associated with

improved survival outcomes (HR=0.67, 95% CI: 0.56-0.80, p=8.9x10^{-6}). No differences were

observed between DRBS groups and age of diagnosis or WHO group.

Grade 4 IDH mutant glioma:

The median survival time for the 83 included individuals with grade 4 *IDH* mutated glioma

tumors was 2.5 years. There were no significant or suggestively important SNP associations with

survival in this group, likely due to small sample size.

IDH wildtype glioma:

The median survival for the 1265 included individuals with an *IDH* wildtype glioma was

16.1 months from time of primary diagnosis. None of the 1393 SNPs reached strict significance

after multiple testing correction, however 3 SNPs in LD in *MSH3* had p<0.0005 associations with

IDH wildtype survival. The top polymorphism, rs6151863-A, an intron variant in *MSH3* on

chromosome 5, was associated with an increase in overall survival (HR=0.67, 95% CI: 0.50-0.89,

p=0.00093), where individuals with any copy of the A allele (n=56) had a median survival time of

20.5 months compared to 15.7 for those with the common G/G genotype (n=1209).

Grade 2/3 IDH wildtype glioma:

A total of 222 individuals with grade 2/3 IDH wildtype gliomas were included in this

analysis, with a median overall survival time of 22.4 months. A single SNP in *MSH6*, rs62139913-

A, was suggestively associated with improved overall survival times (HR=0.26, 95% 0.09-0.76,

p=0.0046). Carriers of any copy of the A allele (n=11) had a median survival of 6.5 years ((5% Ci:

2.0-NA), compared to 1.8 years (95% CI: 1.6-2.2) for the 211 individuals with the G/G genotype.

Grade 4 IDH wildtype glioma:

The median survival for the 1043 included adults with grade 4 *IDH* wildtype gliomas was

15.4 months from initial diagnosis. There were no significant or suggestively important SNP

associations with survival in this group, however the MSH3 association observed in *IDH* wildtype

overall gliomas is only moderately attenuated when subsetting to grade 4, (rs6151863-A,

HR=0.73, 95% CI: 0.54-0.98, p=0.0064), where carriers of any copy of the A allele had a median

survival of 19.1 months, compared to only 15.2 for those with the G/G genotype.

Quantitative Trait Loci analysis:

Using the Genotype-Tissue Expression (GTEx) project (Analysis release v8) and paired

genotype/RNA-seq data from the TCGA, we investigated expression quantitative trait loci (eQTL)

associations for each SNP from **Table 2**. Within GTEx, the rs4949677-A polymorphism was

associated with increased *MSH4* expression in the cerebellum (p=2.53e-11) amongst many other

tissues (**Figure 4A**). We observed that the eQTL effect remained within tumor samples of 323

grade 2/3 *IDH* mutant glioma cases using paired tumor RNAseq and germline genotype data

(**Figure 4B**). The rs146901049-A polymorphism, while located within the *MSH3* gene, was

associated with increased *DHFR* expression in the cortex (p=3.37e-5), an adjacent gene which

shares a promoter region (**Figure 4C**). The association was directionally consistent, but not

significant (p=0.36), amongst tumor samples of grade 2/3 IDH mutant glioma cases from the

TCGA (not reported). The rs3219489-G SNP was a strong splicing QTL for *MUTYH* within the

brain (p=1.51e-12), where the G allele was associated with significantly decreased intron excision

ratios (**Figure 4D**). Bulk tissue gene expression for *MUTYH* across 54 tissue types revealed that

the gene is most highly expressed in the brain (cerebellum) (**Figure 4E**). Amongst the remaining

SNPs in **Table 2,** there were no significant QTL associations within the brain within GTEX, or

within associated tumor types in TCGA.

SNP-TMZ Interaction Analysis:

A total of 1393 glioma cases (480 *IDH* mutant, 913 *IDH* wildtype) from the UCSF AGS and

Mayo Clinic datasets with known temozolomide exposure during first round of treatment were

included. **Table 3** provides a demographic breakdown of each group separated by temozolomide

usage.

In this section, we applied a two-stage analysis: For stage 1, we performed a Cox PH

survival analysis on each of the 1393 SNPs with an included TMZ x SNP interaction term

(significance threshold p<0.005). For stage 2, for all SNPs with significant TMZ-survival

interaction, we calculated Kaplan Meier survival curves for the SNP of interest, separately for

those with TMZ treatment and those without, to filter for TMZ-specific survival associations, using

the log-rank p-values. All results which passed the 2-stage analysis are summarized in **Table 4**,

along with temozolomide and non-temozolomide specific Cox model associations. The full results

set for all considered glioma subtypes are available in **Supplementary File 2**.

IDH mutant gliomas:

The median overall survival time for the 263 included IDH mutant glioma cases with record

of temozolomide during first course of treatment was 10.9 years (95% CI: 9.2-NA), compared to

13.1 years (95% CI: 11.3-17.5) for the 217 without temozolomide. 9 SNPs across four genes

reached the threshold of p<0.005 for an interactive survival effect with temozolomide. Of those

11, two SNPs had significant (KM log rank p<0.05) associations with survival outcomes within

case treated with temozolomide, and no association (p>0.05) with survival for those without

temozolomide (**Table 4**).

The first, rs1540354-T, an intron variant in *MLH1*, was associated with decreased overall

survival only for cases receiving temozolomide (interaction p-value = 0.0044, TMZ KM p-value =

0.00047, non-TMZ KM p-value = 0.71, TMZ-only Cox model: HR=1.70, 95% CI: 1.17-2.47,

p=0.0058 / non-TMZ-only Cox model: HR=0.88, 95% CI:0.55-1.42, p=0.60). Among the 263

temozolomide treated individuals, those with T/T or A/T genotypes (n=84) had an overall survival

time of 6.3 years (95% CI: 5.5-9.2), contrasting to 13.7 years (95% CI:11.3-17.3) for the 179 with

the A/A genotype. The untreated group had indistinguishable survival times: carriers of the T

polymorphism (n=63) lived a median 13.8 years after diagnosis, compared to 13.1 years for those

with the A/A genotype (n=153) (**Figure 5A**).

The second variant, rs71636247-G, an intron in *MSH3* was also associated with

decreased survival amongst cases treated with temozolomide (interaction p-value =0.0045, TMZ

KM p-value = 0.025, non-TMZ KM p-value = 0.73, TMZ-only Cox model: HR=1.93, 95% CI: 1.14-

3.27, p=0.015 / non-TMZ-only Cox model: HR=0.74, 95% CI: 0.40-1.38, p=0.35). The median

survival for individuals treated with temozolomide carrying any copy of the G allele (n=28) was

6.2 years, compared to 12.2 years for the 235 with the A/A genotype. For those without

temozolomide treatment, the median survival times were 12.2 and 13.2 years for those with

(n=24) and without (n=193) any copy of the G allele (**Figure 5C**).

In constructing a DRBS using the two SNPs, individuals were grouped based on the

quantity of polymorphisms (k=2 presented above) present in their germline DNA (0 to 2 sites with

polymorphism). Amongst individuals with temozolomide, in a multivariate cox model adjusting for

age, sex, grade, and the top 10 genetic PCs, a per unit increase in the DRBS was associated with

decreased survival probability (HR=2.23, 95% CI: 1.55-3.20, p=1.56×10^{-5}). Those with both

polymorphisms (n=7) had a median survival time of 4.3 years, those with only one (n=98) survived

a median 7.0 years after diagnosis, and of the n=158 with neither polymorphism, there have not

been enough events to determine a median time (NA, 95% CI: 11.3-NA). For those not treated

with temozolomide during first course of treatment, in an identically parameterized cox model, the

per-unit increase in the DRBS was not associated with survival outcomes (HR=0.90, 95% CI:

0.63-1.28, p=0.56). Median survival times were NA, 11.8, and 13.6 years for those with DRBS

scores of two, one, and zero, respectively (**Figure 5E**).

Grades 2/3 IDH mutant gliomas:

Amongst the grade 2/3 *IDH* mutant cohort of 410 cases, 213 had known temozolomide

treatment, and 197 had confirmed absence of temozolomide treatment. The unadjusted median

survival times were 13.4 years for those with treatment (95% CI: 10.9-17.3) and 15.2 years for

those without (95% CI: 12.8-18.2). 2 SNPs in *XRCC1* reached significance (p<0.005) in stage 1.

Neither passed stage 2 filters in separate KM analyses for cases with and without TMZ treatment

(Supplemental Table 2).

Grades 2/3 IDH mutant 1p/19q codeleted gliomas:

The median survival time for grade 2/3 *IDH* mutant gliomas was further 1p/19q codeletion

was 17.5 years for those treated with temozolomide (n=83), and 17.9 for those without the

treatment (n=69). Nine SNPs across four genes had a suggestively important TMZ-SNP

interaction term (**Supplementary File 2**). Of those, four SNPs in *MSH2*, tagged by lead variant

rs6739909-G (Table 4), passed stage 2 Kaplan-Meier filters. Polymorphism rs6739909-G was

associated with decreased survival amongst individuals treated with temozolomide (interaction p-

value = 0.0045, TMZ KM p-value = 0.030, non-TMZ KM p-value = 0.13, TMZ-only Cox model:

HR=3.77, 95% CI: 1.48-9.58, p=0.0054 / non-TMZ-only Cox model: HR=0.38, 95% CI: 0.11-1.39,

p=0.14). Individuals treated with temozolomide with the G polymorphism (n=19) had a median

survival time of 11.3 years, compared to 20.4 years for the 64 treated individuals with the T/T

genotype. Individuals without temozolomide as first course of treatment had median survival times

of 20.1 and 16.5 years, for carriers and non-carriers of the G allele, respectively.

Grades 2/3 IDH mutant 1p/19q non-codeleted gliomas:

Median survival time for the 119 individuals treated with temozolomide was 10.2 years,

compared to the 11.0 years for the 112 without first-course temozolomide treatment. Two SNPs

in the *LIG4* gene (rs3093772-C, rs3093774-T) had suggestively important TMZ interactive effects

on survival (**Supplemental Table 2**), however neither passed stage 2 thresholding.

Grade 4 IDH mutant gliomas:

This study included only 66 individuals with a grade 4 *IDH* mutant glioma and known

presence/absence of temozolomide as first-course of treatment. The 48 with temozolomide

treatment had a median survival of 42.7 months, compared to the 20.6 months for those 18

individuals without temozolomide. We did not have the sample size necessary to detect

differences, particularly in the stage 2 analysis. Full results are however made available in

Supplemental Table 2.

IDH wildtype gliomas:

A total of 913 individuals with *IDH* wildtype glioma and known presence/absence of

temozolomide during first-course treatment were included in this analysis. The 685 with known

presence of temozolomide had a median survival of 17.8 months, and the 228 with known

absence had a median survival of 15.1 months. A total of 26 SNPs passed stage 1 thresholding

with interaction p-values < 0.005. Of those 26, only rs1052133-G, a missense variant of *OGG1*

(Table 4), passed stage 2 thresholds, and is suggestive of altered survival outcomes for

temozolomide treated *IDH* wildtype gliomas (interaction p-value = 0.0012, TMZ KM p-value =

0.035, non-TMZ KM p-value = 0.29, TMZ-only Cox model: HR=0.78, 95% CI: 0.67-0.92, p=0.0025

/ non-TMZ-only Cox model: HR=1.15, 95% CI: 0.85-1.56, p=0.35). For the 685 with known

temozolomide treatment, the median overall survival time for carriers of the G polymorphism was

18.4 months (n=277), compared to the 16.9 months for C/C genotypes (n=408). For the 228 with

known absence, carriers of the G polymorphism had a median survival time of 14.4 months

(n=102), compared to 16.1 for those with the C/C genotype (n=126).

Grades 2/3 IDH wildtype gliomas:

The 88 individuals with primary grade 2/3 IDH wildtype glioma who received temozolomide

during the initial course of treatment had a median survival time of 23.8 months after primary

diagnosis. The 61 who did not receive the drug during first course had a median survival of 22.9

months. 11 SNPs across two genes (*MSH3* and *LIG4*) reached p<0.005 in stage 1 interaction

analysis. Of those, nine SNPs (in a single LD block) in *MSH3* passed stage 2 filters (**Table 4**).

The association in *MSH3* was captured by the rs34799825-T polymorphism, an intron

variant, where the T allele was associated with drastically improved survival outcomes in the

temozolomide group (interaction p-value = 0.00031, TMZ KM p-value = 0.012, non-TMZ KM p-

value = 0.18, TMZ-only Cox model: HR=0.52, 95% CI: 0.27-1.01, p=0.053 / non-TMZ-only Cox

model: HR=5.19, 95% CI: 2.05-13.12, p=0.00051). For individuals with temozolomide, those with

the C/T or T/T genotype (n=20) had a median survival of 35.6 months (95% CI: 25.9-NA),

compared to 19.9 months (95% CI: 16.7-75.2) for those with the C/C genotype (n=68). For

individuals who did not receive temozolomide in first course of treatment, those with the C/T or

T/T genotypes (n=15) had a median survival time of 17.6 months (95% CI: 9.4-173.6), compared

to the C/C genotype (n=46) of 23.8 months (95% CI: 16.6-74.16).

Grade 4 IDH wildtype gliomas:

The 597 included individuals with grade 4 *IDH* wildtype and known temozolomide

treatment had a median survival of 17.1 months, while the 167 with confirmed absence of

temozolomide as first course treatment had a median 13.7 months survival. In a multivariable Cox

PH model, temozolomide treatment was associated with altered *IDH* wildtype GBM survival

(HR=0.8, 0.66-0.98, p=0.031).

Our stage 1 analysis nominated eight SNPs across two genes with p-values less than

0.005. Of those eight, rs149630102-T in *MSH2* passed stage 2 thresholding (**Table 4**,

Supplementary File 2). An intron variant, rs149630102-T was associated with temozolomide-

specific survival alterations (interaction p-value = 0.0017, TMZ KM p-value = 0.00015, non-TMZ

KM p-value = 0.078, TMZ-only Cox model: HR=1.74, 95% CI: 1.27-2.39, p=0.00052 / non-TMZ-

only Cox model: HR=0.41, 95% CI: 0.23-0.75, p=0.0038). For the temozolomide group, carriers

of the T allele (n=45) had a median survival of 13.2 months (95% CI: 12.3-16.7), compared to

17.6 months (95% CI: 16.5-18.5) for the 552 individuals with the A/A genotype. For the non-

temozolomide group, those with the T allele (n=16) had a median survival of 15.8 months (95%

CI: 9.6-46.9) compared to 13.7 months (95% 11.3-15.5) for those with the A/A genotype (n=151).

Quantitative Trait Loci analysis:

Using the Genotype-Tissue Expression (GTEx) project (Analysis release v8) and paired

genotype/RNA-seq data from the TCGA, we investigated quantitative trait loci associations for

each of the six suggestive SNPs from **Table 4** within the brain/tumor. Within the cortex,

rs1540354-T was an eQTL for RP11-640L9.2 (**Figure 5B**). Within the cerebellum, the same SNP,

rs1540354-T, was a splicing QTL for *LRRFIP2*. The rs71636247-G variant was a significant eQTL

for *MSH3* in the cerebellum, with the G allele associated with increased expression (**Figure 5D**).

Similarly, rs34799825-T was also a significant eQTL for *MSH3* in the cerebellum. Lastly,

rs149630102-T was a significant eQTL for *EPCAM* on chromosome 2 within the hypothalamus.

No SNPs were significant eQTLs for their associated genes within TCGA subtype-specific tumor

samples.

Discussion:

559
We investigated the association of 1393 putatively independent SNPs within 22 DNA

repair genes with overall survival outcomes of 2078 adults with glioma in a meta-analysis of three

datasets with molecular subtype specificity. We further investigated if these germline

polymorphisms modified survival specifically for patients treated with temozolomide. We observed

statistically significant polygenic associations with both overall survival, and temozolomide-

specific outcomes, broadly amongst *IDH* mutant gliomas.

Grade 2/3 *IDH* mutant gliomas are comprised of both astrocytoma and oligodendroglioma

tumors, both which have generally favorable prognoses in comparison with other glioma

subgroups. In this mixed group, we observed 4 polymorphisms (in *MLH1, MSH4, MSH3,* and

MUTYH) which, when combined, significantly stratified survival trajectories of individuals within

this tumor group. Cases with none of the four risk SNPs had a median survival of nine years

longer than those with any of the four. For three of the four polymorphisms, we presented possible

functional alterations within the brain. The rs4949677-A polymorphism was associated with

elevated *MSH4* expression both in normal brain and tumor tissues. The rs146901049-A

polymorphism, while located within the *MSH3* gene, was associated with a decreased expression

of *DHFR* within the brain. *DHFR,* highly expressed in gliomas, is a crucial metabolic enzyme in

the folic acid signaling pathway, and has been hypothesized to contribute to glioma cell

proliferation and to decreased chemosensitivity to temozolomide, and has previously been

nominated as a target for therapeutics[27,28]. The results presented here, however, provide

evidence that a germline decrease in *DHFR* expression (in normal brain) is detrimental to glioma

survival. We found that carriers of the G polymorphism at rs3219489 in *MUTYH* exhibited

improved survival compared to CC carriers amongst adults with grade 2/3 *IDH* mutant gliomas.

Located at chromosome locus 1p34.3—1p32.1, the *MUTYH* gene encodes for a BER enzyme,

MYH glycosylase, responsible for the repair of oxidized guanine incorrectly paired with adenine,

one of the most pervasive forms of oxidative damage, by excising the undamaged adenine

base[29,30]. Of all tissues available in the GTEx database, *MUTYH* is most highly expressed in the

brain (cerebellum). The *MUTYH* rs3219489 C to G polymorphism results in an amino acid change

from glutamine to histidine, which evidence from GTEx QTL analysis suggests results in

alternative splicing of the *MUTYH* protein in the brain, a likely functional alteration to the BER

mechanism and a potential mediator of glioma survival. The rs3219489-G allele has been

previously associated with decreased survival amongst lung cancer patients who received

platinum-based chemotherapy[31] and increased risk of recurrence in oral squamous cell carcinoma

patients receiving chemoradiotherapy[32]. Further germline alterations in *MUTYH* have been most

strongly linked with an elevated risk of colorectal cancer via inheritable colon polyposis, primarily

amongst individuals with European ancestry[33], and others have been extensively described in

terms of their ability to promote somatic mutations, including C>A mutations[34]. Further functional

work is needed to understand the role of rs3219489 in promoting somatic mutations and the

effects of this potential sQTL in glioma.

We identified four germline DNA repair polymorphisms (in *MSH4*, *ERCC1*, and *ERCC2*)

which were each associated with increased survival times of individuals with low grade 1p/19q

non-codeleted glioma. We demonstrated that the presence of any of these four was significantly

associated a nearly double increase in median survival times compared to those with none of the

polymorphisms. Based on eQTL analyses, the most common of the four polymorphisms,

rs3916788-C allele is shown to downregulate the mRNA expression of *ERCC2* in a variety of

tissues, and has been previously implicated with improved overall survival in a study of individuals

with esophageal squamous cell cancer[35]. Further, three of the associated polymorphisms are

located on the q arm of chromosome 19 (specifically, 19q13.32, an area near a putative glioma

suppressor region[36]), a copy of which is commonly lost in glioma tumors. We suspect that

disruption of these DNA repair pathways maybe related to the favorable prognosis of 1p/19q co-

deleted gliomas, however functional studies are required.

The role of temozolomide in treating glioblastomas is well-understood, with a clear

improvement in patient outcomes when combined with other standard-of-care treatments. Our

study found suggestive evidence of a single DNA repair germline risk factor (rs149630102-T in

MSH2) modifying this glioblastoma effect. Interestingly, the identified SNP was associated with

altered survival in opposite directions, depending on if the group received temozolomide. For the

group of grade 4 *IDH* wildtype gliomas without temozolomide, the T allele was suggestively

associated with improved survival, whereas the same allele was suggestive of decreased survival

for cases who received the drug. This could be related to the repair of TMZ-induced mutagenic

adducts and a threshold effect, providing protection in TMZ-naive subjects, and a detriment to

TMZ-treated subjects by repairing enough of the TMZ induced mutations to avoid cell death and

therefore promoting greater number of somatic mutations in a surviving clone. Using GTEx, we

found that rs149630102-T was associated with increased expression of the *EPCAM* gene in non-

cancer brain and was also suggestively associated with both *EPCAM* and *MSH2* expression in

TCGA glioblastoma tumor samples (not shown). A 2014 study demonstrated an association

between increased *EPCAM* expression and decreased grade 4 glioma survival time[37], which is

consistent with the line of evidence observed in this study for individuals who received

temozolomide. A 2015 study also presented in vivo evidence that decreased *MSH2* levels caused

a reduction in response to temozolomide in glioblastoma[38]. When comparing survival curves,

those without the rs149630102-T polymorphism and treated with temozolomide had the longest

median survival time of all groups, suggesting temozolomide may provide survival benefits only

to this group. To confirm this speculation, further work into the link between this polymorphism,

EPCAM, *MSH2*, other possible functional mechanisms, and the interaction with temozolomide is

both warranted and necessary.

As is well described by a growing body of literature, temozolomide-induced hypermutation at

recurrence is common amongst individuals with lower grade *IDH* mutant glioma, with only *MGMT*

promoter methylation level at primary diagnosis as a possible biomarker for hypermutation and

general sensitivity to the treatment[12]. While hypermutation and *MGMT* status are unknown in our

study participants, we identified two germline polymorphisms, in *MLH1* and *MSH3* genes, which

were associated with poor outcomes for individuals with *IDH* mutant glioma treated with

temozolomide, and no differential effect in the non-temozolomide group. Both SNPs were

significantly associated with altered expression of RNA transcripts in the brain, suggesting likely

functional alterations to the mismatch repair mechanisms during temozolomide-induced damage

repair of the tumor cells, possibly diminishing the efficacy of the mechanism. A reduction in *MLH1*

expression has been previously associated with temozolomide resistance in GBM cell lines[39],

consistent with the directional effect (non-significant) of rs1540354-T on *MLH1* expression. While

not conducted in glioma, previous cell-line analyses have demonstrated *MSH3* deficiency lead to

increased chemosensitivity and cell apoptosis, independent of the role of *MLH1*, in colon

carcinoma cells[40]. Our combined evidence of rs71636247-G having associations with both

decreased survival and increased *MSH3* expression in the brain remains consistent with this

previous observation. We show that the presence of either of these two polymorphisms resulted

in drastically decreased median survival times, even with rigorous significance thresholds. As

such, these two SNPs warrant further clinical investigation as our results generate the hypothesis

that temozolomide may not be an appropriate treatment for individuals harboring these germline

polymorphisms, and alternative treatments should be prioritized. Although not included here,

these results were replicated with only minor attenuation when excluding all grade 4 *IDH* mutant

glioma cases.

Resistance to therapeutics continues to be a major cause of treatment failure for individuals

with cancer. Anticipating how germline differences can alter response to temozolomide and other

possible chemotherapy options can help to influence the course of treatment clinicians take in the

care of patients, specifically if treatment should include temozolomide or an alternative drug. In

the treatment of *IDH* mutant 1p/19q codeleted oligodendrogliomas, there is controversy whether

either temozolomide or procarbazine, lomustine, and vincristine (PCV) in combination with

radiation therapy provides better patient outcomes, with the ongoing CODEL clinical trial

investigating the impact on progression-free survival for each drug[41]. Also, the recently completed

promising clinical trials of the drug, vorasidenib, an *IDH* inhibitor, presents another possible

treatment avenue for *IDH* mutant gliomas[42]. As therapeutic options progress, clinicians and

patients have more options in the treatment of *IDH* mutant gliomas, identifying predictors of

response to treatment, like the SNPs identified in this study, can help guide personalized

treatment courses.

Our findings should be considered with the following limitations. Our included meta-analysis

is from a set of historic cohorts. As such, we lack the full suite of somatic molecular markers to

adhere to strict WHO 2021 classification guidelines, and we lack knowledge of *MGMT*

methylation, a relatively recently identified and costly phenotype to measure. The cohorts also do

not include robust information on the recurrent tumor, including temozolomide-induced hypermutation. Our results may not extend to non-European populations, as the included subjects were chosen to have at least 70% genetically estimated European ancestry. Our study of temozolomide was limited to a binary yes/no history of known drug usage during the first course of treatment; we could not further investigate the role of timing and amounts of temozolomide administered on survival outcomes. Ongoing studies which collect detailed treatment information across the course of the disease will be key to determining if the effects presented in this study are indeed isolated to just first-course treatment. Despite these limitations, this analysis is one of the most extensive studies of glioma germline genetics and survival with available molecular subtyping, long-term follow-up, and temozolomide utilization.

This study presents germline polygenic associations in DNA repair pathways which are associated with significant impacts on overall survival and drug response in individuals with specific glioma subtypes. We posit potential mechanisms using quantitative trait loci analysis for a select set of SNPs. While further investigation into both a validation dataset and proper functional studies are needed, this study lays the groundwork for the integration of germline SNPs in determining accurate clinical management and the best therapeutic options in the treatment of gliomas.

References:

1. Ostrom QT, Price M, Neff C, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015–2019. *Neuro-Oncol*. 2022;24(Supplement_5):v1-v95. doi:10.1093/neuonc/noac202

2. Weltgesundheitsorganisation. *WHO Classification of Tumours of the Central Nervous*

System. Revised 4th edition. (Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds.).

International Agency for Research on Cancer; 2016.

3. Molinaro AM, Taylor JW, Wiencke JK, Wrensch MR. Genetic and molecular epidemiology of

adult diffuse glioma. *Nat Rev Neurol*. 2019;15(7):405-417. doi:10.1038/s41582-019-0220-2

4. Johnson DR, O'Neill BP. Glioblastoma survival in the United States before and during the

temozolomide era. *J Neurooncol*. 2012;107(2):359-364. doi:10.1007/s11060-011-0749-4

5. Nowell PC. The Clonal Evolution of Tumor Cell Populations: Acquired genetic lability

permits stepwise selection of variant sublines and underlies tumor progression. *Science*.

1976;194(4260):23-28. doi:10.1126/science.959840

6. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability — an evolving hallmark of

cancer. *Nat Rev Mol Cell Biol*. 2010;11(3):220-228. doi:10.1038/nrm2858

7. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. *Cell*.

2011;144(5):646-674. doi:10.1016/j.cell.2011.02.013

8. Singh N, Miner A, Hennis L, Mittal S. Mechanisms of temozolomide resistance in

glioblastoma - a comprehensive review. *Cancer Drug Resist*. Published online 2020.

doi:10.20517/cdr.2020.79

9. Johnson BE, Mazor T, Hong C, et al. Mutational Analysis Reveals the Origin and Therapy-

Driven Evolution of Recurrent Glioma. *Science*. 2014;343(6167):189-193.

doi:10.1126/science.1239947

10. Touat M, Li YY, Boynton AN, et al. Mechanisms and therapeutic implications of

hypermutation in gliomas. *Nature*. 2020;580(7804):517-523. doi:10.1038/s41586-020-2209-

9

11. Yu Y, Villanueva-Meyer J, Grimmer MR, et al. Temozolomide-induced hypermutation is

associated with distant recurrence and reduced survival after high-grade transformation of

low-grade *IDH* -mutant gliomas. *Neuro-Oncol*. 2021;23(11):1872-1884.

doi:10.1093/neuonc/noab081

12. Mathur R, Zhang Y, Grimmer MR, et al. MGMT promoter methylation level in newly

diagnosed low-grade glioma is a predictor of hypermutation at recurrence. *Neuro-Oncol*.

2020;22(11):1580-1590. doi:10.1093/neuonc/noaa059

13. Wang LE, Bondy ML, Shen H, et al. Polymorphisms of DNA Repair Genes and Risk of

Glioma. *Cancer Res*. 2004;64(16):5560-5563. doi:10.1158/0008-5472.CAN-03-2181

14. Lubbe SJ, Di Bernardo MC, Chandler IP, Houlston RS. Clinical Implications of the

Colorectal Cancer Risk Associated With *MUTYH* Mutation. *J Clin Oncol*. 2009;27(24):3975-

3980. doi:10.1200/JCO.2008.21.6853

15. Butkiewicz D, Rusin M, Enewold L, Shields PG, Chorazy M, Harris CC. Genetic

polymorphisms in DNA repair genes and risk of lung cancer. *Carcinogenesis*.

2001;22(4):593-597. doi:10.1093/carcin/22.4.593

16. Silva SN, Tomar M, Paulo C, et al. Breast cancer risk and common single nucleotide

polymorphisms in homologous recombination DNA repair pathway genes XRCC2, XRCC3,

NBS1 and RAD51. *Cancer Epidemiol*. 2010;34(1):85-92. doi:10.1016/j.canep.2009.11.002

17. Eckel-Passow JE, Drucker KL, Kollmeyer TM, et al. Adult diffuse glioma GWAS by

molecular subtype identifies variants in *D2HGDH* and *FAM20C*. *Neuro-Oncol*.

2020;22(11):1602-1613. doi:10.1093/neuonc/noaa117

18. Melin BS, Barnholtz-Sloan JS, Wrensch MR, et al. Genome-wide association study of

glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and

non-glioblastoma tumors. *Nat Genet*. 2017;49(5):789-794. doi:10.1038/ng.3823

19. Wrensch M, Jenkins RB, Chang JS, et al. Variants in the CDKN2B and RTEL1 regions are

associated with high-grade glioma susceptibility. *Nat Genet*. 2009;41(8):905-908.

doi:10.1038/ng.408

20. Jenkins RB, Wrensch MR, Johnson D, et al. Distinct germ line polymorphisms underlie

glioma morphologic heterogeneity. *Cancer Genet*. 2011;204(1):13-18.

doi:10.1016/j.cancergencyto.2010.10.002

21. Ceccarelli M, Barthel FP, Malta TM, et al. Molecular Profiling Reveals Biologically Discrete

Subsets and Pathways of Progression in Diffuse Glioma. *Cell*. 2016;164(3):550-563.

doi:10.1016/j.cell.2015.12.028

22. Guerra G, Kachuri L, Wendt G, et al. The immunogenetics of viral antigen response is

associated with subtype-specific glioma risk and survival. *Am J Hum Genet*.

2022;109(6):1105-1116. doi:10.1016/j.ajhg.2022.04.011

23. The 1000 Genomes Project Consortium, Corresponding authors, Auton A, et al. A global

reference for human genetic variation. *Nature*. 2015;526(7571):68-74.

doi:10.1038/nature15393

24. Bi W, Fritsche LG, Mukherjee B, Kim S, Lee S. A Fast and Accurate Method for Genome-

Wide Time-to-Event Data Analysis and Its Application to UK Biobank. *Am J Hum Genet*.

2020;107(2):222-233. doi:10.1016/j.ajhg.2020.06.003

25. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide

association scans. *Bioinforma Oxf Engl*. 2010;26(17):2190-2191.

doi:10.1093/bioinformatics/btq340

26. Rizvi AA, Karaesmen E, Morgan M, et al. gwasurvivr: an R package for genome-wide

survival analysis. Schwartz R, ed. *Bioinformatics*. 2019;35(11):1968-1970.

doi:10.1093/bioinformatics/bty920

27. Zhao M, Tan B, Dai X, et al. DHFR/TYMS are positive regulators of glioma cell growth and

modulate chemo-sensitivity to temozolomide. *Eur J Pharmacol*. 2019;863:172665.

doi:10.1016/j.ejphar.2019.172665

28. Fawal MA, Jungas T, Davy A. Inhibition of DHFR targets the self-renewing potential of brain

tumor initiating cells. *Cancer Lett*. 2021;503:129-137. doi:10.1016/j.canlet.2021.01.026

29. Shibutani S, Takeshita M, Grollman AP. Insertion of specific bases during DNA synthesis

past the oxidation-damaged base 8-oxodG. *Nature*. 1991;349(6308):431-434.

doi:10.1038/349431a0

30. Michaels ML, Miller JH. The GO system protects organisms from the mutagenic effect of the

spontaneous lesion 8-hydroxyguanine (7,8-dihydro-8-oxoguanine). *J Bacteriol*.

1992;174(20):6321-6325. doi:10.1128/jb.174.20.6321-6325.1992

31. Singh A, Singh N, Behera D, Sharma S. Genetic Investigation of Polymorphic OGG1 and

MUTYH Genes Towards Increased Susceptibility in Lung Adenocarcinoma and its Impact

on Overall Survival of Lung Cancer Patients Treated with Platinum Based Chemotherapy.

Pathol Oncol Res. 2019;25(4):1327-1340. doi:10.1007/s12253-017-0372-6

32. Senghore T, Chien HT, Wang WC, et al. Predictive value of genetic variants XRCC1

rs1799782, APEX1 rs1760944, and MUTYH rs3219489 for adjuvant concurrent

chemoradiotherapy outcomes in oral squamous cell carcinoma patients.

Pharmacogenomics J. 2020;20(6):813-822. doi:10.1038/s41397-020-0170-5

33. Nielsen M, Morreau H, Vasen HFA, Hes FJ. MUTYH-associated polyposis (MAP). *Crit Rev*

Oncol Hematol. 2011;79(1):1-16. doi:10.1016/j.critrevonc.2010.05.011

34. Robinson PS, Thomas LE, Abascal F, et al. Inherited MUTYH mutations cause elevated

somatic mutation rates and distinctive mutational signatures in normal human cells. *Nat*

Commun. 2022;13(1):3949. doi:10.1038/s41467-022-31341-0

35. Zhang R, Zhou F, Cheng L, et al. Genetic variants in nucleotide excision repair pathway

predict survival of esophageal squamous cell cancer patients receiving platinum-based

chemotherapy. *Mol Carcinog.* 2018;57(11):1553-1565. doi:10.1002/mc.22877

36. Smith JS, Tachibana I, Pohl U, et al. A Transcript Map of the Chromosome 19q-Arm Glioma

Tumor Suppressor Region. *Genomics.* 2000;64(1):44-50. doi:10.1006/geno.1999.6101

37. Chen X, Ma WY, Xu SC, et al. The overexpression of Epithelial cell adhesion molecule

(EpCAM) in glioma. *J Neurooncol.* 2014;119(1):39-47. doi:10.1007/s11060-014-1459-5

38. McFaline-Figueroa JL, Braun CJ, Stanciu M, et al. Minor Changes in Expression of the

Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to

Temozolomide. *Cancer Res.* 2015;75(15):3127-3138. doi:10.1158/0008-5472.CAN-14-3616

39. Shinsato Y, Furukawa T, Yunoue S, et al. Reduction of MLH1 and PMS2 confers

temozolomide resistance and is associated with recurrence of glioblastoma. *Oncotarget*.

2013;4(12):2261-2270. doi:10.18632/oncotarget.1302

40. Park JM, Huang S, Tougeron D, Sinicrope FA. MSH3 mismatch repair protein regulates

sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma

cells. *PloS One*. 2013;8(5):e65369. doi:10.1371/journal.pone.0065369

41. Jaeckle KA, Ballman KV, Van Den Bent M, et al. CODEL: phase III study of RT, RT + TMZ,

or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial

study design. *Neuro-Oncol*. 2021;23(3):457-467. doi:10.1093/neuonc/noaa168

42. Mellinghoff IK, van den Bent MJ, Blumenthal DT, et al. Vorasidenib in IDH1- or IDH2-Mutant

Low-Grade Glioma. *N Engl J Med*. Published online June 4, 2023:NEJMoa2304194.

doi:10.1056/NEJMoa2304194

Figures and Tables for '**The impact of germline variants in DNA repair pathways on**

survival and temozolomide toxicity in adults with glioma'

Figure 1: Included glioma subgroups based on prognostically significant molecular
markers and tumor grade. Tumor types were coarsely split first by IDH mutation status, and
then by further by tumor grade at primary diagnosis. Grade 2/3 IDH mutant gliomas were further
stratified by the 1p/19q chromosomal arm codeletion phenotype. Boxes with included sample
size are used to highlight the eight subgroups analyzed in this study.

Figure 2: Co-occurrence of four germline DNA repair polymorphisms in MLH1, MSH4, MSH3, and MUTYH, and the associated survival trajectories of individuals with grade 2/3 IDH mutant gliomas. *Individuals were grouped based on the presence of four suggestively important survival SNPs: rs1046901049-A (MSH3), rs494677-AA (MSH4), rs4647218-AA (MLH1), and rs3219489-CC (MUTYH). The effect polymorphisms were chosen such that each had a survival decreasing effect. Possible groups consist of individuals with zero to four of the highlighted polymorphisms. Individuals with 2 or more were grouped due to small group sizes. A) Upset plot highlighting the common co-occurrences of the four suggestive survival SNPs. B) The percentage of cases with 1p/19q codeletion phenotype, by group. C) Pie charts highlighting the distribution of tumor grades within each of the four groups. Border color indicates the group. D) Pie charts highlighting the age distribution of individuals within each group. Border color indicates the group. D) Unadjusted percent survival distributions for adults with Grade 2/3 IDH mutant gliomas, stratified by the count of highlighted DNA repair polymorphisms, demonstrates the associated survival disadvantage of present polymorphisms. A curve highlighting individuals with at least one of the polymorphisms is also included (grey). Dashed vertical lines represent median survival times, measured in years since diagnosis. Cases were collected from the UCSF Adult Glioma Study, the Mayo Clinic, and The Cancer Genome Atlas.*

Figure 2: Co-occurrence of four germline DNA repair polymorphisms in MSH4, ERCC2, and
ERCC1, and the associated survival trajectories of individuals with grade 2/3 IDH mutant
1p/19q non-codeleted gliomas. Individuals were grouped based on the presence of four
suggestively important survival SNPs: rs5745366-T (MSH4), rs3918604-C (ERCC2),
rs144057986-C (ERCC1), rs3916788-C (ERCC2). Groups consist of individuals with zero to four
of the highlighted polymorphisms. Individuals with three or four were grouped due to small group
sizes.   A) Upset plot highlighting the common co-occurrences of the four suggestive survival
SNPs. B) Pie charts highlighting the distribution of tumor grades within each of the four groups.
Border color indicates the group. C) Pie charts highlighting the age distribution of individuals within
each group. Border color indicates the group. D) Unadjusted percent survival distributions for
adults with Grade 2/3 IDH mutant 1p/19q non-codeleted gliomas, stratified by the count of
highlighted DNA repair polymorphisms, demonstrates the associated survival benefits of
accumulated polymorphisms. A curve highlighting individuals with at least one of the
polymorphisms is also included (grey). Dashed vertical lines represent median survival times,
measured in years since diagnosis. Cases were collected from the UCSF Adult Glioma Study,
the Mayo Clinic, and The Cancer Genome Atlas.

Figure 4: Statistically significant brain-specific QTL associations in cancer-free donors
from the Genotype-Tissue Expression (GTEx) project and in tumor tissues from TCGA
LGG/GBM projects amongst BER/MMR SNPs with suggestive effects on glioma survival.
We utilized data from GTEx and TCGA to explore functional changes associated with each of the
11 SNPs suggestively associated with altered glioma survival outcomes. Three SNPs had
significant QTL associations within normal brain tissue, with one demonstrating the same QTL
association within tumor samples. (A) The A allele of rs4949677 is associated with increased
MSH4 mRNA expression within the brain. (B) The A allele of rs4949677 is associated with
increased MSH4 mRNA expression within tumor tissue of IDH mutant grade 2/3 glioma samples.
(C). The A allele of rs1496901049 is associated with decreased expression of DHFR within
cancer-free brain cortex samples. (D). The G allele of rs3219489 is associated with a significant
decrease in the intron-excision ratio of MUTYH mRNA within healthy brain, thus is a splicing QTL.
(E). In complement with the result of (D), MUTYH is highly expressed in the cerebellum region of
the brain, the highest across all 54 tissue types.

879 ***Figure 5: Germline polymorphisms in MLH1 and MSH3 are associated with negative***
880 ***survival outcomes amongst cases with IDH mutant glioma receiving temozolomide during***
881 ***first course of treatment. A)*** *Unadjusted percent survival distributions for adults with IDH mutant*
882 *glioma tumors with or without temozolomide treatment further stratified by germline polymorphism*
883 *rs1540354-T demonstrates the SNP is associated with negative survival outcomes only for cases*
884 *who were treated with temozolomide.* ***B)*** *GTEx eQTL analysis from cancer-free brain tissues*
885 *demonstrates rs1540354-T is associated with increased expression of RP11-640L9.2 in the*
886 *cortex. C) Unadjusted percent survival distributions for adults with IDH mutant glioma tumors with*
887 *or without temozolomide treatment further stratified by germline polymorphism rs71636247-G*
888 *demonstrates the SNP is associated with negative survival outcomes only for cases who were*
889 *treated with temozolomide.* ***D)*** *GTEx eQTL analysis from cancer-free brain tissues demonstrates*
890 *rs71636247-G is associated with increased expression of MSH3 in the cerebellum.* ***E)*** *Unadjusted*
891 *percent survival distributions for adults with IDH mutant glioma tumors with or without a history of*
892 *temozolomide treatment, stratified by the co-occurrence of germline DNA repair SNPs rs1540354-*
893 *T (MLH1) and rs71636247-G (MSH3) demonstrate that the combination of both SNPs is*
894 *associated with the worst overall survival outcomes, only for individuals who received*
895 *temozolomide. The SNPs have no association with survival in the non-temozolomide group.*
896 *Vertical dashed lines represent median overall survival times, measured in years since primary*
897 *diagnosis. Pie charts describe the distribution of tumor grades within each of the six groups. All*
898 *cases were a part of either the UCSF Adult Glioma Study or the Mayo Clinic datasets.*

899

901 **Table 1: Clinical and molecular summary of included adults with glioma across three**
902 **datasets**

	UCSF AGS	Mayo Clinic	TCGA
Number of cases	1158	235	685
Age at diagnosis (Median + IQR)	52 (IQR: 20)	50 (IQR: 24)	52 (IQR: 26)
Sex (% Male)	61.92%	62.13%	59.27%
Self-report race (% White)	99.22%	94.89%	NA
IDH			
Wildtype	67.44%	56.17%	51.39%
Mutant	32.56%	43.83%	48.61%
1p/19q			
Codeleted	10.88%	13.19%	18.54%
Non-codeleted	86.44%	75.74%	80.15%
NA	2.68%	11.06%	1.31%
TERT			
Wildtype	29.10%	31.06%	20.44%
Mutant	60.88%	64.68%	18.83%
NA	10.02%	4.26%	60.73%
Grade			
2	20.47%	21.28%	26.28%
3	17.53%	29.36%	30.22%
4	62.00%	49.36%	43.50%
Histology			
Astrocytoma	19.86%	23.40%	20.58%
Oligodendroglioma	12.69%	6.38%	21.02%
Glioblastoma*	62.26%	47.23%	43.50%
Oligoastrocytoma	5.18%	22.98%	14.89%
Diagnosis Year Median (min, max, IQR)	2004 (1991, 2012, IQR: 7)	2008 (1991, 2013, IQR: 5)	NA
% of cases diagnosed pre-1999	12.52%	5.11%	NA
% of cases diagnosed pre-2005	52.42%	20.43%	NA
% Censored (no known death event)	16.67%	25.53%	59.71%
% Censored before 2 years	0.26%	13.62%	47.30%
Chemotherapy (% known Chemo)	78.50%	80.00%	NA
Temozolomide (% known TMZ)	69.78%	59.57%	NA
Radiation (% known RT)	83.77%	85.96%	NA

903 NA: not available information
904 *Group contains *IDH* wildtype and mutant. World Health Organization 2021 guidelines now classify IDH
905 mutant Glioblastoma as Grade 4 Astrocytoma
906

907 **Table 2: Multivariate cox proportional hazards analysis of genetic variants in mismatch**

908 **repair and base excision repair genes with overall survival amongst major glioma**

909 **molecular subtypes.**

Gene	Chr.	SNP	Effect Allele	Allele Freq.	HR (95% CI)	*P*
IDH **mutant glioma**						
MLH1	3	rs4647218	G	0.44	0.79 (0.68-0.93)	0.0034
IDH **mutant grade 2/3 glioma**						
MLH1	3	rs4647218	G	0.44	0.74 (0.61-0.88)	0.0014
MSH4	1	rs4949677	A	0.26	1.33 (1.07-1.65)	0.0018
MSH3	5	rs146901049	A	0.017	3.28 (1.70-6.33)	0.0029
MUTYH	1	rs3219489	G	0.25	0.69 (0.54-0.88)	0.0034
IDH **mutant grade 2/3 1p/19q codeleted glioma**						
MSH2	2	rs12615967	G	0.12	2.04 (1.22-3.33)	0.0032
IDH **mutant grade 2/3 1p/19q non-codeleted glioma**						
MSH4	1	rs5745366	T	0.036	0.33 (0.15-0.72)	0.0010
ERCC2	19	rs3916804	C	0.16	0.44 (0.28-0.70)	0.0027
ERCC2	19	rs3916788	C	0.42	0.62 (0.47-0.83)	0.0033
ERCC1	19	rs144057986	C	0.18	0.58 (0.42-0.82)	0.0045
IDH **wildtype glioma**						
MSH3	5	rs6151863	A	0.026	0.67 (0.50-0.89)	0.0009
IDH **wildtype grade 2/3 glioma**						
MSH6	2	rs62139913	A	0.027	0.26 (0.09-0.76)	0.0046
IDH **wildtype grade 4 glioma**						
MSH3	5	rs6151863	A	0.026	0.73 (0.54-0.98)	0.0064

910
911

912 **Table 3: Clinical and molecular summary of included adults with glioma with known**

913 **usage/absence of temozolomide treatment.**

| | IDH mutant | | IDH wildtype | |
	Received TMZ	No TMZ	Received TMZ	No TMZ
Number of cases	263	217	685	228
Age at diagnosis (Median + IQR)	40 (IQR: 16)"	39 (IQR: 18)	58 (IQR: 16)	58 (IQR: 18)
Sex (% Male)	60.84%	57.60%	64.82%	58.77%
Self-report race (% White)	98.10%	98.16%	98.25%	100%
1p/19q				
Codeleted	31.56%	31.80%	0.15%	1.75%
Non-codeleted	63.12%	59.91%	97.81%	93.42%
NA	5.32%	8.29%	2.04%	4.83%
TERT				
Wildtype	52.85%	53.00%	16.79%	17.98%
Mutant	36.88%	33.18%	77.23%	69.74%
NA	10.27%	13.82%	5.99%	12.28%
Grade (% of total)				
2	35.36%	64.98%	3.36%	13.16%
3	45.63%	25.81%	9.49%	13.60%
4	19.01%	9.22%	87.15%	73.25%
Histology (% of total)				
Astrocytoma	36.88%	34.56%	11.24%	15.79%
Oligodendroglioma	27.00%	32.72%	0.73%	6.58%
Glioblastoma	19.01%	8.29%	87.15%	73.25%
Oligoastrocytoma	17.11%	24.42%	0.88%	4.39%
Diagnosis Year	2007	2003	2007	2002
Median (min, max, IQR)	(1998, 2013, IQR: 5)	(1991, 2012, IQR: 10)	(2001, 2013, IQR: 5)	(1991, 2013, IQR: 6)
% of cases diagnosed pre-1999	0.76%	29.95%	0%	39.47%
% of cases diagnosed pre-2005	34.60%	67.74%	34.60%	78.95%
% Censored (no known death event)	45.63%	43.78%	3.36%	6.58%
% Censored before 2 years	7.22%	4.61%	0.58%	0.88%
Radiation (% known RT)	72.24%	52.53%	97.52%	87.72%

916 **Table 4: Association analysis of genetic variants in mismatch repair and base excision**

917 **repair genes with temozolomide-specific survival amongst glioma molecular subtypes.**

Gene	Chr.	SNP	Effect Allele	Allele Freq.	*P**	TMZ cox PH model			Non-TMZ cox PH model		
						KM *P*	HR (95% CI)	*P*	KM *P*	HR (95% CI)	*P*
IDH mutant glioma											
MLH1	3	rs1540354	T	0.18	0.0026	0.00047	1.70 (1.17-2.47)	0.0058	0.71	0.88 (0.55-1.42)	0.60
MSH3	5	rs71636247	G	0.043	0.0045	0.025	1.93 (1.14-3.27)	0.015	0.73	0.74 (0.40-1.38)	0.35
IDH mutant grade 2/3 1p/19q codeleted glioma											
MSH2	2	rs6739909	G	0.11	0.0045	0.030	3.77 (1.48-9.58)	0.0054	0.13	0.38 (0.11-1.39)	0.14
IDH wildtype glioma											
OGG1	1	rs1052133	G	0.23	0.0012	0.034	0.78 (0.67-0.92)	0.0025	0.29	1.15 (0.85-1.56)	0.35
IDH wildtype grade 2/3 glioma											
MSH3	5	rs34799825	T	0.13	0.0003	0.012	0.52 (0.27-1.01)	0.053	0.18	5.19 (2.05-13.12)	0.0005
IDH wildtype grade 4 glioma											
MSH2	2	rs149630102	T	0.040	0.0017	0.00015	1.74 (1.27-2.39)	0.00052	0.078	0.41 (0.23-0.75)	0.0038

918 *: P-value of SNP x TMZ interaction term in Cox PH model
919 KM *P*: Unadjusted Kaplan-Meier log rank p-value
920
921